Baxter pays $100m upfront for ex-US rights to pancreatic cancer candidate
This article was originally published in Scrip
Baxter is to pay $100m upfront for ex-US rights (excluding Taiwan) for Merrimack Pharmaceuticals' MM-398 (nanoliposomal irinotecan injection), also known as nal-IRI, a drug candidate for pancreatic cancer.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.